Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Integrated BiopharmaINBP 36 Return-on-Tangible-Equity is -17.28% as of Mar. 2026. GuruFocus rates INBP with a GF Score™ of 36/100 and a GF Value™ of $0.26 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,880 Consumer Packaged Goods companies, Integrated Biopharma ranks worse than 85.43% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Integrated Biopharma's annualized net income for the quarter that ended in Mar. 2026 was $-3.35 Mil. Integrated Biopharma's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $19.38 Mil. Therefore, Integrated Biopharma's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -17.28%.
The historical rank and industry rank for Integrated Biopharma's Return-on-Tangible-Equity or its related term are showing as below:
INBP'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -8.28 Med: 13.71 Max: 103.22
Current: -8.28
During the past 13 years, Integrated Biopharma's highest Return-on-Tangible-Equity was 103.22%. The lowest was -8.28%. And the median was 13.71%.
INBP's Return-on-Tangible-Equity is ranked worse than 85.43% of 1880
companies
in the Consumer Packaged Goods industry
Industry Median: 7.87
vs INBP: -8.28
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Integrated Biopharma Return-on-Tangible-Equity Related Terms
Integrated Biopharma Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Integrated Biopharma's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INBP vs HCWC, PAVS, BABB: Return-on-Tangible-Equity Comparison
For the Packaged Foods subindustry, Integrated Biopharma's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integrated Biopharma Return-on-Tangible-Equity vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Integrated Biopharma's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Integrated Biopharma's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -17.28% mean?
Integrated Biopharma (INBP) has a Return-on-Tangible-Equity of -17.28% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Integrated Biopharma and its competitors. According to the industry distribution chart, Integrated Biopharma ranks #1606 out of 1880 companies in the Consumer Packaged Goods industry, placing it in the top 85.4%.
Is Integrated Biopharma's Return-on-Tangible-Equity too high?
Integrated Biopharma's current Return-on-Tangible-Equity is -17.28%. Based on the distribution chart, Integrated Biopharma ranks #1606 out of 1880 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Integrated Biopharma has a GF Score™ of 36/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Integrated Biopharma's Return-on-Tangible-Equity compare to HCWC and PAVS?
According to the Consumer Packaged Goods industry distribution chart, Integrated Biopharma ranks #1606 out of 1880 companies for Return-on-Tangible-Equity. This places Integrated Biopharma in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.87. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Consumer Packaged Goods company?
The median Return-on-Tangible-Equity among Consumer Packaged Goods companies is 7.87, based on 1,880 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Integrated Biopharma and its competitors. For the Consumer Packaged Goods industry, the median Return-on-Tangible-Equity is 7.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integrated Biopharma's current Return-on-Tangible-Equity is -17.28%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integrated Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Integrated Biopharma (INBP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.26, compared to a current price of $0.16 — trading 38.5% below its estimated fair value. The current Return-on-Tangible-Equity is -17.28%. Integrated Biopharma's overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Integrated Biopharma (INBP), the current Return-on-Tangible-Equity is -17.28% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integrated Biopharma (INBP) Overvalued in 2026?
Based on GuruFocus' analysis, Integrated Biopharma stock appears to be undervalued.
The current stock price of $0.16 is trading 38.5% below its estimated GF Value™ of $0.26.
GuruFocus considers Integrated Biopharma to be Possible Value Trap.
Key valuation signals for INBP:
Return-on-Tangible-Equity: -17.28%
GF Value™: $0.26 vs. price of $0.16 (38.5% below fair value)
No single metric tells the full story. See the INBP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integrated Biopharma Inc is a pharmaceutical company engaged in manufacturing, distributing, marketing, and selling vitamins, nutritional supplements, and herbal products. It operates in two segments: Contract Manufacturing and Other Nutraceutical Businesses. Key revenue is generated from the Contract Manufacturing segment, which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers.
36GF Score
Get the complete analysis for INBP
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INBP has been successfully added to your 
